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Abstract
Background: Statins have anticancer properties by acting as competitive inhibitors of the mevalonate pathway. They also
have anti-inflammatory activity, but their role in suppressing inflammation in a cancer context has not been investigated to
date.
Methods: We have analyzed the relationship between statin use and tumor-associated macrophages (TAMs) in a cohort of
262 surgically resected primary human lung adenocarcinomas. TAMs were evaluated by multiplex immunostaining for the
CD68 pan-TAM marker and the CD163 protumorigenic TAM marker followed by digital slide scanning and partially auto-
mated quantitation. Links between statin use and tumor stage, virulence, and cancer-specific survival were also investigated
in a wider cohort of 958 lung adenocarcinoma cases. All statistical tests were two-sided.
Results: We found a statin dose-dependent reduction in protumorigenic TAMs (CD68þCD163þ) in both stromal (P¼ .021) and
parenchymal (P¼ .003) compartments within regions of in situ tumor growth, but this association was lost in invasive
regions. No statistically significant relationship between statin use and tumor stage was observed, but there was a statin
dose-dependent shift towards lower histological grade as assessed by growth pattern (P¼ .028). However, statin use was a
predictor of slightly worse cancer-specific survival (P¼ .032), even after accounting for prognostic variables in a multivariable
Cox proportional hazards survival model (hazard ratio¼1.38, 95% confidence interval ¼ 1.04 to 1.84).
Conclusions: Statin use is associated with reduced numbers of protumorigenic TAMs within preinvasive lung
adenocarcinoma and is related to reduced tumor invasiveness, suggesting a chemo-preventive effect in early tumor develop-
ment. However, invasive disease is resistant to these effects, and no beneficial relationship between statin use and patient
outcome is observed.
Statins are a class of safe and well-tolerated cholesterol-lower-
ing drugs commonly used for cardio-protective benefits. They
are one of the most prescribed medications, and thus there
has been interest in their relationship with malignancy.
However, the link between statin use and cancer incidence
and mortality is controversial, with some studies showing a
relationship between lower cancer incidence (1–3) or reduced
cancer mortality (4,5) and other studies not supporting these
conclusions (6–8).
Despite a lack of clear correlation between statin use and
outcomes for patients, there is abundant preclinical evidence to
support their anticancer functions (9,10). The best characterized
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mechanism through which statins exert their anticancer effect
is through their ability to suppress the mevalonate pathway by
inhibition of 3-hydroxy-3-methyl-glutaryl-CoA reductase, lead-
ing to reduced cholesterol production and protein prenylation,
both of which are vital for cancer cell proliferation and survival
(9,11). Statins also have anti-inflammatory functions indepen-
dent of their ability to lower cholesterol (12). This is achieved
through a variety of mechanisms, including suppression of cy-
tokine and cell adhesion molecule expression (13–15) and inhi-
bition of NF-jB signalling (13,16,17).
Cancer development is dependent on an interaction be-
tween tumor cells and the microenvironment (18) with in-
flammation being a key factor in this (19). Monocytes or
macrophages are important contributors to chronic inflamma-
tion through their plasticity and capacity to become polarized
by the tumor microenvironment to form tumor-associated
macrophages (TAMs) (20,21). The two main cancer-relevant
TAM subtypes are the M2-polarized immunosuppressive
prooncogenic and M1-polarized tumoricidal antioncogenic
forms (20,22). A link between higher prooncogenic TAM num-
ber in the tumor stroma and worse clinical prognosis has been
demonstrated for several cancers, including lung cancers (23–
25). Studies in animal models support an association between
TAMs and enhanced tumor progression (26), and depleting
TAMs by splenectomy results in regression of oncogenic
KRAS-driven mouse lung premalignant and advanced lesions
(27).
In searching for therapies that may counteract the protu-
morigenic activities of TAMs, statins have been considered a
possibility. The aim of this study was to investigate the impact
of statin use on TAM location, number, and polarity and corre-
late these with analysis of tumor proliferation, stage, grade, and
survival in a cohort of lung adenocarcinoma samples from
patients undergoing surgical resections with curative intent.
Methods
Patient Cohort
A continuous cohort of 958 primary lung adenocarcinomas
resected with curative intent between the years 1998 and 2015
was identified from the University Hospitals of Leicester NHS
Trust histopathology database under a project protocol sup-
ported by the regional ethics committee (ref 157104/UHL11363)
and made use of the consent exemption detailed in the UK
Human Tissue Act 2004 (www.hta.gov.uk). Cases were excluded
if there was a possibility of nonprimary lung origin or synchro-
nous primary pulmonary nonadenocarcinoma. All patients
were treatment naı¨ve at the time of surgery. All key prognostic
variables were compiled from pathology databases and from
patient notes, including patient sex, age, performance status,
and key determinants of stage such as tumor size and nodal in-
volvement at the time of surgery. The involvement of pleura,
presence or absence of vascular invasion, and predominant
growth pattern was confirmed by dual examination of diagnos-
tic slide images by two histopathologists (J. Le Quesne and J.
Baena). Drug history data were obtained from hospital data-
bases and patient notes. Statin use status was defined at the
time of admission for surgery, and duration of statin use was
calculated as the date of treatment initiation to the date of
surgery.
Tissue Microarrays
A subset of 262 resected primary lung adenocarcinoma sam-
ples from 2012 to 2014 was assembled into tissue microarrays
(TMAs). Scanned images of all diagnostic blocks were exam-
ined, and regions were selected for inclusion into TMAs. In
cases of mixed histological growth pattern, most cores repre-
senting diverse growth patterns were sampled, with the sam-
pling of both in situ and invasive areas being the priority. Five
TMA blocks containing 31-mm cores per case were con-
structed using a semiautomatic array machine TMArrayer
(Pathology Device, San Diego, California, USA). We cut 5-mm
sections for subsequent staining and analysis.
Immunohistochemistry
Slides were dewaxed by placing in 100% xylene for 10 minutes
each. They were rehydrated through graded alcohols (2  1 min-
ute in 99% [v/v] Industrial Methylated Spirits (IMS) followed by
1 minute in 95% [v/v] IMS) and then placed in running tap water
for 5 minutes. Antigen retrieval was performed by placing slides
in citrate buffer (0.01 M citric acid, pH 6.0) and microwaving at
full power for 20 minutes. Peroxidase blocking solution, sup-
plied with the Polymer detection system (Leica Biosystems,
Wetzlar, Germany; RE7230-K and RE7270-K), was applied to the
slides for 5 minutes to neutralize endogenous peroxidases. After
washing in Tris-buffered saline (TBS), slides were placed in a
protein block solution supplied with the polymer detection sys-
tem kit for 5 minutes and then washed twice in TBS for
5 minutes each. The slides were incubated for 1 hour at room
temperature either with a single antibody or cocktail of primary
antibodies using appropriate dilutions. Slides were washed in
TBS for 5 minutes before applying the appropriate secondary
antibodies. Primary antibodies used were a 1:400 dilution of a
CD68 rabbit polyclonal antibody (Sigma-Aldridge (Merck; St
Louis, Missouri USA), clone HPA048982), a 1:600 dilution of a
CD163 mouse monoclonal antibody (Novocastra (Leica
Biosystems), clone 10D6), and a 1:100 dilution of a Ki67 antibody
(Abcam (Cambridge, UK) AB15580). For double immunohisto-
chemistry, the dual staining system from MenaPath
(A.Menarini Diagnostics, Wokingham, UK) was used (MP-
XLCT525-K6) according to the manufacturer’s instructions.
Table 1. Statin use in lung adenocarcinoma cohort in tissue
microarrays
Variable No. (%)
Statin use
No statin 149 (56.9)
Statin 112 (42.8)
Unknown 1 (0.4)
Statin type
Atorvastatin 29 (25.9)
Simvastatin 75 (67.0)
Other 8 (7.1)
Statin dose
540 mg 51 (45.5)
40 mg 61 (54.5)
Statin duration
51 mo 39 (34.8)
1–6 mo 35 (31.3)
46 mo 36 (32.1)
Unknown 2 (2.7)
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After staining, slides were counterstained by incubation in
Mayer’s hematoxylin for 30 seconds before dehydration and
mounting.
Digital Scanning and Image Analysis
Stained slides were scanned using a Hamamatsu scanner
NanoZoomer-XR Digital slide scanner (Hamamatsu Photonics
UK Ltd, Welwyn Garden City, UK), and images were analyzed
using Visiopharm software (Horsholm, Denmark). Luminal,
stromal, and tumor areas were separated manually in
Visiopharm on the counterstained immunohistochmical (IHC)
images, with reference to hemotoxylin and eosin (H&E)-stained
serial sections where necessary. Cores in which
microanatomical region assignments were difficult were further
examined by a subspecialty respiratory pathologist (J. Le
Quesne) and consensus segmentation was applied. Tumor
islands or parenchyma, stroma, and luminal compartments
were analyzed separately. An app was designed using
Visiopharm software to identify and count all macrophages
(CD68-positive) and protumorigenic polarized macrophages
(dual positivity for CD68 and CD163). Individual cores were cate-
gorized as in situ or invasive by two pathologists (J. Baena and J.
Le Quesne) working in a blinded manner, with discussion and
consensus assignment of equivocal cores. In situ cores con-
tained only in situ or lepidic growth pattern malignancy, with
cytologically malignant cells growing on the surface of architec-
turally normal lung alveoli. “Invasive” cores contained invasive
growth pattern morphology (acinar, papillary, solid, and
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Figure 1. In situ macrophage density and polarity analysis. A) Automated macrophage polarity detection and quantification. B) A low-power view of a representative 1-
mm core of invasive human pulmonary adenocarcinoma with superimposed manual segmentation into epithelial or stromal (yellow), luminal (pink), and necrotic
(green) areas. C) High-power view of a dual-stained protumorigenic macrophage. D) Medium-power view showing multiple macrophages with diverse staining pat-
terns. E) Medium-power view with superimposed automated cell classifications. IHC ¼ immunohistochemical; TAM ¼ tumor-associated macrophage; TMA ¼ tissue
microarray.
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Figure 2. Compartmentalized macrophage number and polarity. A) Quantitation of CD68þ tumor-associated macrophages (TAMs) in the tumor parenchyma, stroma,
and lumina. B) Quantitation of CD163þ/CD68þ TAMs in the tumor parenchyma, stroma, and lumina. C) Quantitation of CD68þ TAMs overall and in the tumor paren-
chyma, stroma, and lumina subcompartments of in situ and invasive regions. D) Quantitation of CD163þ/CD68þ TAMs overall and in the tumor parenchyma, stroma,
and lumina subcompartments of in situ and invasive regions. These data were established by immunohistochemical staining of the tissue microarrays (TMAs) harbor-
ing 262 lung adenocarcinoma samples with antibodies for CD68 and CD163 followed by automated cell classification and counting. Numbers were normalized to the
areas of manually drawn tissue compartments.
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micropapillary) as defined by World Health Organization diag-
nostic criteria.
Statistical Analysis
Associations between continuous variables were assessed by
Spearman rank correlation. Associations between binary varia-
bles and between binary and ordinal variables were assessed
with the Pearson v2 test. Trends in continuous variables across
ordered groups were assessed using the Cuzick test for trend.
Differences in continuous variables between unpaired groups
were assessed using the Mann-Whitney U test. Stata SE 15.1 was
used for all statistical figure preparation and statistical and sur-
vival analyses.
Survival Analysis
Time-to-event data on cancer-specific survival status and time
from surgery to date of last-known status were obtained from
the cohort database using a follow-up time of 6 years. The
cancer-specific survival endpoint used as events only deaths
directly attributable to lung cancer (ie, within part I of the UK
medical certificate of cause of death) and non-lung cancer
deaths were censored. Survival was modeled using Kaplan-Meier
analysis, and differences between groups were assessed by the
log-rank test. A multivariable Cox proportional hazards model
was built to incorporate all available additional known prognos-
tic variables. The proportional hazards assumption was tested
by examination of log-log plots. All tests were two-sided and a
P value of less than .05 was considered statistically significant.
Results
We first assessed the distribution of TAMs within lung adenocar-
cinoma samples by multiplex analysis of TMAs constructed from
a cohort of 262 lung adenocarcinoma samples, the details of
which are provided in Table 1. TMAs were immunostained with
antibodies for the pan-macrophage marker CD68 and the puta-
tive prooncogenic macrophage marker CD163. Macrophages
were identified and classified algorithmically in digital images,
and subclasses of macrophages were counted in parenchymal,
stromal, and luminal tumor compartments. The staining
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Figure 3. Relationship between macrophage polarity and tumor cell proliferation. Tissue microarrays (TMAs) were immunostained with antibodies for Ki67, CD163,
and CD68 followed by automated quantification of the stained cells in stromal (A), parenchymal (B), and luminal (C) areas. The gray triangles above the figures indicate
results of tests for trend across ordered categories; only stromal macrophages are related to tumor cell proliferation.
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patterns were analyzed by digital scanning and quantitation
(Figure 1).
The density of total CD68þ TAMs (Figure 2A) and the propor-
tion of CD68þ/CD163þ TAMs (Figure 2B) were both statistically
significantly lower in parenchymal (ie, epithelial) tumor areas
compared with tumor stroma. Individual tissue cores were clas-
sified as being of either in situ or invasive pattern, and we found
that TAM densities were statistically significantly higher in in-
vasive areas compared with in situ areas in both parenchymal
and stromal zones (Figure 2C). In luminal areas, the reverse re-
lationship was seen in that there were fewer luminal macro-
phages within invasive tumor areas. This perhaps reflects the
physiological differences between lumina within in situ disease,
which are continuous with healthy airways that have their own
pulmonary alveolar macrophage populations, compared with
lumina, which arise de novo in disordered areas of invasive tu-
mor growth. Invasive areas showed a mild elevation of protu-
morigenic polarization overall (P¼ .028), although this was not
observed when analyzed by microanatomical subcompartment
(Figure 2D).
We investigated the link between TAMs and tumor prolifera-
tion and found a strong positive association between the den-
sity of CD68þ/CD163þ TAMs in the stroma and proliferation of
tumor cells as determined by Ki67 staining (Figure 3A), but no
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Figure 4. Relationship between statin use and tumor-associated macrophage (TAM) number and polarity within in situ and invasive regions of lung adenocarcinoma
samples. A) Quantitation of CD68þ TAMs overall and in microanatomical compartments of in situ tumor regions from statin- and nonstatin-treated patients. The ex-
tended triangle above the figure indicates a statistically significant trend within luminal macrophages. All other categories were not statistically significant. B)
Quantitation of CD68þ TAMs in microanatomical compartments of invasive tumor regions. No statistically significant trends were observed. C) Quantitation of the
fraction of prooncogenic CD68þ/CD163þ TAMs in microanatomical compartments of in situ tumor regions. The extended triangles above the figure indicate statisti-
cally significant trends across parenchymal macrophages (orange) and stromal macrophages (blue). All other categories were not statistically significant. D)
Quantitation of the fraction of prooncogenic CD68þ/CD163þ TAMs in microanatomical compartments of invasive tumor regions. No statistically significant trends
were observed. Data for A–D were established by immunohistochemical staining of the tissue microarrays harboring 262 lung adenocarcinomas with antibodies for
CD68 and CD163 followed by automated quantification of the stained cells and (for A and B) normalization against compartment area.
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such association was detected in parenchymal (Figure 3B) or lu-
minal (Figure 3C) areas. Protumorigenic TAMs such as those
that can be identified by dual staining with CD68 and CD163 are
known to promote tumor cell proliferation, angiogenesis, inva-
sion, and metastasis as well as to suppress T-cell–mediated
antitumor immune responses through paracrine mechanisms
(20,24,25). Our finding of an association of CD68þ/CD163þ TAMs
with increased tumor cell proliferation is consistent with this
protumorigenic function and argues in favor of a direct mito-
genic, paracrine effect rather than a reduction in immune-
mediated cytotoxicity.
We next investigated whether there was an association be-
tween statin use and TAM number and polarity by quantitation
of CD68/CD163 staining in statin users and nonusers among the
262 lung adenocarcinoma cohort. There was a marked dose-
dependent trend towards reduced numbers of CD68þ luminal
macrophages in areas of in situ tumor growth (Figure 4A), but
this was not seen in areas of invasive growth (Figure 4B). With
regard to macrophage polarity, increasing statin dosage showed
a statistically significant association with diminished CD68þ/
CD163þ staining in parenchymal and stromal areas within in
situ tumor regions (Figure 4C). Thus, within in situ areas, both
the density of luminal macrophages and the degree of proonco-
genic polarization are reduced with higher statin dosage, with
the net result being that the absolute number of prooncogenic
macrophages is reduced. This relationship, however, was ab-
sent in invasive regions (Figure 4D).
To investigate if reduced CD68þ/CD163þ TAMs within in
situ regions has an impact on lung adenocarcinoma develop-
ment, we first assessed the link between statin use and patho-
logical tumor staging. Stage data were obtained for our entire
tumor cohort of 958 patients, and information on statin use
among this cohort is presented in Table 2. Although there
appeared to be greater stage I tumors among the higher dose
statin users, this trend was not statistically significant
(Figure 5A).
A complication of correlating pathological stage with statin
use is that stage at presentation is affected by multiple con-
founding factors, including the likely earlier presentation of sta-
tins users in the medical system and more regular monitoring
than nonusers. We therefore investigated the relationship be-
tween statin use and tumor virulence (“grade”) by examining
the predominant growth pattern, which is a measure of tumor
virulence not known to be associated with clinical stage.
Pulmonary adenocarcinomas fall into low-, medium-, and high-
risk groups based on their predominant growth pattern (in situ
vs acinar/papillary vs solid/micropapillary) (28–30). This classifi-
cation is well established in the lung cancer pathology field and
is likely to form the basis of a formal clinical grading system in
the near future. Most lung adenocarcinomas exhibit several pat-
terns of growth, and a minor proportion of in situ growth is
common even in advanced cases; this can represent either a
remaining part of the low-grade precursor lesion or an area of
surface outgrowth of potentially invasive malignancy (31).
Crucially, we found a statistically significant relationship be-
tween higher statin use and diminishing virulence as assessed
by tumor growth pattern (Figure 5B), indicating that the transi-
tion to higher grade invasive growth patterns is delayed by
statin activity.
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Figure 5. Relationship between statin use and lung adenocarcinoma stage and
grade. A) Tumor stage in statin users and nonusers. Overall pathological tumor
stage was determined and compared across the treatment groups. The bar
graph indicates the proportion of tumors of each stage within patients receiving
no statin, less than 40 mg/d statin, or greater than or equal to 40 mg/d statin. A
pair wise test comparing all three stages among the greater than or equal to 40
mg/d statin users with low or nonstatin users is indicated. B) Predominant tu-
mor growth pattern in statin users and nonusers. The predominant growth pat-
tern was determined by inspection of whole H&E sections according to World
Health Organization diagnostic criteria. Predominantly in situ tumors were clas-
sified as low risk, predominantly acinar or papillary cases as medium risk, and
solid and micropapillary predominant cases as high risk. The bar graph indi-
cates the proportion of tumors of each risk category receiving no statin, less
than 40 mg/d statin, or greater than or equal to 40 mg/d statin. A pair wise test
comparing all three risk groups among the greater than or equal to 40-mg/d
statin users with low or nonstatin users is indicated.
Table 2. Statin use in entire lung adenocarcinoma cohort
Variable No. (%)
Statin use
No statin 538 (56.2)
Statin 282 (29.4)
Unknown 138 (14.4)
Statin type
Atorvastatin 77 (27.3)
Simvastatin 177 (62.8)
Other 28 (9.9)
Statin dose
540 mg 152 (53.9)
40 mg 130 (46.1)
Statin duration
51 mo 94 (33.3)
1–6 mo 85 (30.1)
46 mo 101 (35.8)
Unknown 2 (0.7)
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To determine if statin use has a long-term beneficial effect
on outcomes for lung adenocarcinoma patients, we investigated
the relationship with survival in this larger cohort but found
that statin users had slightly worse cancer-specific survival
compared with nonusers, although this relationship was not
dose dependent (Figure 6). When incorporated into a multivari-
able Cox proportional hazards survival model, statin use
remained an independent predictor of poor outcome (Figure 6),
although the involvement of other comorbidities related to the
prescription of statin such as cardiovascular disease and stroke
cannot be excluded from this analysis.
Discussion
There is no clear evidence for statins having either a beneficial
or detrimental effect on cancer incidence or survival from can-
cer from epidemiological investigations (32). However, there has
been much interest in investigating their potential as cancer
preventive or therapeutic agents because they have powerful
antiproliferative and antii-nflammatory properties within
in vitro and in animal models (9,10). We have focused our atten-
tion on the anti-inflammatory roles of statins because macro-
phages are major mediators of inflammation and TAMs have
both pro- and antitumorigenic functions (20,22). We reasoned
that an impact on TAMs could potentially explain the contro-
versial data linking statins with cancer imparted from epidemi-
ological investigations.
Here, we provide evidence that statin use is associated with
a reduction of protumorigenic TAMs within areas of in situ tu-
mor growth in human lung adenocarcinomas (Figure 4C). The
fact that this correlation is dose dependent reinforces this rela-
tionship. At present, it is not clear whether these effects are re-
lated to the ability of statins to inhibit the mevalonate pathway
within TAMs with subsequent effects on macrophage polarity
and tumor cell behavior, within tumor cells that then affects
TAMs through paracrine mechanisms, or through some other
mevalonate-independent function. Further investigations are
required to unravel the precise mechanisms involved.
Stromal macrophages demonstrating M2 polarity are known
to be associated with more aggressive disease in pulmonary
adenocarcinoma (23–25), and, indeed, we have found that protu-
morigenic macrophage polarization correlates with tumor cell
proliferation in primary tumor tissue (Figure 3A). Given published
evidence for their oncogenic functions (20,24,25), it is logical to as-
sume that lowering the density of M2-polarized TAMs within in
situ regions by statins is likely to have the biological effect of
slowing progression to invasive disease. Thus, potentially,
through their association with diminished protumorigenic TAM
polarity, statins can provide chemopreventive benefit. This idea
is supported by the observed relationship between statin use and
a shift towards a lower risk growth pattern (Figure 5B). However, a
direct causal link between statin use, suppressed protumorigenic
TAMs, and reduced growth pattern remains to be proven.
We find that the relationship between statin use and reduced
protumorigenic TAMs is lost in invasive regions of human lung
adenocarcinoma, suggesting that the dependency on paracrine
signaling from TAMs is restricted to the in situ growth phase or
perhaps that statin resistance emerges as the disease progresses.
The reasons for this are not clear but may indicate alterations in
the TAMs themselves or in the tumor-TAM interaction associated
with transition to malignancy. It also suggests that any clinical
value that statins may have in the treatment or prevention of
lung adenocarcinoma may be most apparent very early in the
natural history of the tumor, possibly years before malignancy
becomes clinically apparent. Certainly, in our cohort of patients
with established surgically treated disease, no overall benefit of
statin use is seen. Additionally, any beneficial survival effects
may have been partially masked by comorbidities associated
with statin use such as cardiac disease.
In summary, our findings support a mechanistic role for
statin drugs in the slowing or prevention of lung cancer progres-
sion via alterations in macrophage polarity. However, causal
links between statin use, suppressed protumorigenic TAMs, and
reduced tumor virulence remain to be proven mechanistically
in appropriate model systems.
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Multivariate cancer-specific survival model
Variable HR P 95% CI
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Figure 6. Relationship between statin use and cancer-specific survival. Kaplan-Meier plot showing the relationship between cancer-specific patient survival and statin
therapy in the patient cohort. NB: two statin users were excluded from the survival model because they died on the day of surgery. The table on the right shows a mul-
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